Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites

被引:0
|
作者
MingChen Ba
机构
关键词
Intraperitoneal hyperthermic perfusion; Laparoscopy; Chemotherapy; Gastric cancer; Malignant ascites;
D O I
暂无
中图分类号
R730.5 [肿瘤治疗学];
学科分类号
100214 ;
摘要
AIM:To investigate the procedure, feasibility and effects of laparoscopeassisted continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy (CHIPC) in treatment of malignant ascites induced by peritoneal carcinomatosis from gastric cancers. METHODS: From August 2006 to March 2008, the laparoscopic approach was used to perform CHIPC on 16 patients with malignant ascites induced by gastric cancer or postoperative intraperitoneal seeding. Each patient underwent CHIPC three times after laparoscopeassisted perfusion catheters placing. The first session was completed in operative room under general anesthesia, 5% glucose solution was selected as perfusion liquid, and 1500 mg 5 fluorouracil (5FU) and 200 mg oxaliplatin were added in the perfusion solution. The second andthird sessions were performed in intensive care unit, 0.9% sodium chloride solution was selected as perfusion liquid, and 1500 mg 5FU was added in the perfusion solution alone. CHIPC was performed for 90 min at a velocity of 450600 mL/min and an in flow temperature of 43 ± 0.2℃.RESULTS: The intraoperative course was uneventful in all cases, and the mean operative period for laparoscopeassisted perfusion catheters placing was 80 min for each case. No postoperative deaths or complications related to laparoscopeassisted CHIPC occurred in this study. Clinically complete remission of ascites and related symptoms were achieved in 14 patients, and partial remission was achieved in 2 patients. During the followup, 13 patients died 29 mo after CHIPC, with a median survival time of 5 mo. Two patients with partial remission suffered from port site seeding and tumor metastasis,and died 2 and 3 mo after treatment. Three patients who are still alive today survived 4, 6 and 7 mo, respectively. The Karnofsky marks of patients (5090) increased significantly (P < 0.01) and the general status improved after CHIPC. Thus satisfactory clinical efficacy has been achieved in these patients treated by laparoscopic CHIPC. CONCLUSION: Laparoscopeassisted CHIPC is a safe, feasible and effective procedure in the treatment of debilitating malignant ascites induced by unresectable gastric cancers.
引用
收藏
页码:1901 / 1907
页数:7
相关论文
共 50 条
  • [41] Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy to Treat Gastric Cancer With Ascites and/or Peritoneal Carcinomatosis: Results From a Chinese Center
    Yang, Xiao-Jun
    Li, Yan
    Yonemura, Yutaka
    JOURNAL OF SURGICAL ONCOLOGY, 2010, 101 (06) : 457 - 464
  • [42] Safe temperature range for intraoperative and early postoperative continuous hyperthermic intraperitoneal perfusion in a swine model of experimental distal gastrectomy with Billroth II reconstruction
    Li, Sheng
    Zhang, Yong-Lei
    Sun, Jia-Yuan
    Hua, Ya-Wei
    Wu, Pei-Hong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [43] Safety and Effectiveness of High-Precision Hyperthermic Intraperitoneal Perfusion Chemotherapy in Peritoneal Carcinomatosis: A Real-World Study
    Ba, Mingchen
    Cui, Shuzhong
    Long, Hui
    Gong, Yuanfeng
    Wu, Yinbing
    Lin, Kunpeng
    Tu, Yinuo
    Zhang, Bohuo
    Wu, Wanbo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] Efficacy of postoperative intraperitoneal hyperthermic perfusion chemotherapy with oxaliplatin+5-Fluorouracil in the treatment of gastric cancer patients with peritoneal carcinomatosis
    Yan, Kangpeng
    Wu, Kun
    Yan, Lan
    Liang, Lei
    Yuan, Yujun
    JOURNAL OF BUON, 2019, 24 (04): : 1587 - 1594
  • [45] The role of “closed abdomen” hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience
    L. Orgiano
    F. Pani
    G. Astara
    C. Madeddu
    S. Marini
    A. Manca
    Giovanni Mantovani
    Supportive Care in Cancer, 2016, 24 : 4293 - 4299
  • [46] Evaluation of efficacy and safety for compound kushen injection combined with intraperitoneal chemotherapy for patients with malignant ascites: A systematic review and meta-analysis
    Yu, Hui-Bo
    Hu, Jia-Qi
    Han, Bao-Jin
    Cao, Hui-Juan
    Chen, Shun-Tai
    Chen, Xin
    Xiong, Hong-Tai
    Gao, Jin
    Du, Yan-Yuan
    Zheng, Hong-Gang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [47] SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation
    Yehong Bin
    Dong Lan
    Wenguang Bao
    Haiyan Yang
    Shengsheng Zhou
    Fengxiang Huang
    Man Wang
    Zhigang Peng
    Trials, 23
  • [48] SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation
    Bin, Yehong
    Lan, Dong
    Bao, Wenguang
    Yang, Haiyan
    Zhou, Shengsheng
    Huang, Fengxiang
    Wang, Man
    Peng, Zhigang
    TRIALS, 2022, 23 (01)
  • [49] A single-center randomized controlled study of intraperitoneal hyperthermic chemoperfusion in combination of recombinant human tumor necrosis factor (TNF) in treatment of malignant ascites caused by advanced abdominal cancers
    Wu, Lexia
    Zhu, Wanshan
    Meng, Jincheng
    Wu, Jiaming
    Li, Luzhen
    Fang, Cantu
    Zhang, Huatang
    MEDICINE, 2022, 101 (48) : E31883
  • [50] Effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy on serum levels of HE4 and DJ-1 in patients with advanced recurrent ovarian cancer
    Su, Xianhui
    Sun, Xuewen
    Kang, Yanhui
    Dai, Yuna
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2022, 38 (04) : 872 - 877